Antibody generation
We provide flexible and professional antibody generation of both polyclonal and monoclonal antibodies through our trusted partners, together with a large range of associated services including optimisation and production of antibody from existing hybridomas, adaptation of cells to serum-free conditions, bulk antibody production and purification. We also provide custom synthesis services for the generation of the peptide antigens.
Antibody generation services
Here at Altabioscience, we have a wide range of options for the production of both monoclonal antibodies and polyclonal antibodies. Contact us to learn more or if you have any questions.
Antibody generation process
Process of monoclonal antibody generation
Our monoclonal antibody generation process is identified by five phases. A typical monoclonal antibody project may yield up to 10 positive wells at the fusion screening stage and, after cloning, can deliver two or three stable monoclonal antibodies. However, the number of monoclonal antibodies generated in a project cannot be guaranteed. The project is charged per line of limiting dilution cloning to allow for ultimate flexibility and for greater numbers of candidates to be brought forward past the first stage. This gives a greater degree of flexibility in comparison to being priced by a set number of hybridomas. Read more about custom monoclonal antibodies.
Process of polyclonal antibody generation
The standard inoculation procedure for a polyclonal antibody in a rabbit involves six immunisations at two-week intervals and three bleeds (with an additional pre-immune bleed). If required, this program can be modified and/or extended to fit specific requirements, provided it complies with the licence held by the animal facility. The standard program uses Freund’s Adjuvant but other adjuvants are available on request. Test bleeds are available for client assays after each bleed if required. The terminal serum is delivered at the end of the program, either raw or purified. Read more about custom polyclonal antibodies.
Latest news
AltaBioscience Announces Dr Lisa Mansell as New Managing Director
AltaBioscience, a leading provider of custom synthesis and analytical services for the life science, food and alternative protein industries, is pleased to announce the appointment of Dr Lisa Mansell as the new Managing Director. Dr Lisa Mansell will be succeeding Mrs Marion Peak, who is retiring after a distinguished tenure with the company.
Visit us at the Babraham Research Campus on 13th November 2024
AltaBioscience will be holding a mini exhibition at the Babraham Research Campus. Come talk to our team on 13th November 2024.
Meet us at the CBNP17 Symposium
We are pleased to announce that we’ll be sponsoring the seventeenth Chemistry and Biology of Natural Products Symposium (CBNP17) that will take place at the University of Warwick on 4-5 July 2024. This event is a satellite meeting of Directing Biosynthesis VII, which is taking place in Birmingham on 1-3 July. This event will feature exciting talks from leading UK […]